 Home > Medical News > Medical Science News > New research is expected to change the clinical practice of nasopharyngeal carcinoma

New research is expected to change the clinical practice of nasopharyngeal carcinoma

 Last Update: 2021-08-26
 Source: Internet
 Author: User

Tags

hydrochloride drug

respiratory acidosis results

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

New research is expected to change the clinical practice of nasopharyngeal carcinoma

Phase III study results of teriprizumab combined with chemotherapy for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma released

The new study is expected to change clinical practice, new research NPC NPC is expected to change clinical practiceTerry Plymouth monoclonal antibody combined with chemotherapy in first-line treatment of recurrent or metastatic nasopharyngeal carcinoma Phase III research released Terry Plymouth monoclonal antibody combined with chemotherapy in first-line treatment Phase III research results of recurrent or metastatic nasopharyngeal carcinoma released

Recently, "Nature-Medical" published the latest multi-center randomized phase III clinical study of teriprizumab or placebo combined with chemotherapy for the first-line treatment of advanced nasopharyngeal carcinoma, and disclosed the first-line treatment of domestic innovative drug teriprizumab combined with chemotherapy Results of the Phase III study of recurrent or metastatic nasopharyngeal carcinoma (JUPITER-02 study)
.

It is reported that Xu Ruihua, professor of Sun Yat-sen University Cancer Center, is the corresponding author of the article, and professors Mai Haiqiang and Chen Qiuyan are the co-first authors of the article

In June of this year, Xu Ruihua was invited to the global oncology event-the American Society of Clinical Oncology (ASCO) annual meeting as the first Chinese scholar's keynote speech on the JUPITER-02 research
.

Nasopharyngeal cancer, commonly known as "Cantonese tumor", has a low incidence in most parts of the world, but it is more common in southern China and Southeast Asia
.

At present, the global incidence of nasopharyngeal cancer is 1.

The JUPITER-02 study led by Xu Ruihua is currently the world's largest phase III study of immunotherapy for nasopharyngeal carcinoma
.

It evaluated the efficacy and safety of teriprizumab or placebo combined with GP chemotherapy in the first-line treatment of recurrent/metastatic nasopharyngeal carcinoma.

According to reports, from November 2018 to October 2019, the study enrolled 289 patients in China and Singapore, who were randomized 1:1 into the teriprizumab combined chemotherapy group or the placebo combined chemotherapy group
.

The results showed that the progression-free survival of the teriprizumab combined with chemotherapy group was significantly improved.

"At present, the overall survival benefit trend of the triplimumab group has been observed, the risk of death has been reduced by 40%, and the overall safety of the study is better and manageable
.

" Xu Ruihua said that the JUPITER-02 study is expected to change the nose in the future.

It is understood that the U.
S.
Food and Drug Administration will give China-produced teriprizumab PD-1 antibody first-line indications based on the results of the JUPITER-02 study
.

"This research will have an important impact on the formulation of international clinical practice guidelines for nasopharyngeal cancer.